valsartan/hydrochlorothiazide ratiopharm 320 mg / 12.5 mg tabletti, kalvopäällysteinen
ratiopharm gmbh - valsartanum,hydrochlorothiazidum - tabletti, kalvopäällysteinen - 320 mg / 12.5 mg - valsartaani ja diureetit
candesartan/hydrochlorothiazide teva 32 mg / 25 mg tabletti
teva pharma b.v. - candesartanum cilexetilum,hydrochlorothiazidum - tabletti - 32 mg / 25 mg - kandesartaani ja diureetit
candesartan/hydrochlorothiazide stada 16 mg / 12.5 mg tabletti
stada arzneimittel ag - candesartanum cilexetilum,hydrochlorothiazidum - tabletti - 16 mg / 12.5 mg - kandesartaani ja diureetit
telmisartan/hydrochlorothiazide sandoz 40 mg / 12.5 mg tabletti, päällystetty
sandoz a/s sandoz a/s - telmisartanum,hydrochlorothiazidum - tabletti, päällystetty - 40 mg / 12.5 mg - telmisartaani ja diureetit
telmisartan/hydrochlorothiazide sandoz 80 mg / 25 mg tabletti, päällystetty
sandoz a/s sandoz a/s - telmisartanum,hydrochlorothiazidum - tabletti, päällystetty - 80 mg / 25 mg - telmisartaani ja diureetit
telmisartan/hydrochlorothiazide mylan 40 mg / 12.5 mg tabletti
mylan ab - telmisartanum,hydrochlorothiazidum - tabletti - 40 mg / 12.5 mg - telmisartaani ja diureetit
telmisartan/hydrochlorothiazide ratiopharm 80 mg / 25 mg tabletti
ratiopharm gmbh - telmisartanum,hydrochlorothiazidum - tabletti - 80 mg / 25 mg - telmisartaani ja diureetit
lisinopril/hydrochlorothiazide orion 20 mg / 12.5 mg tabletti
orion corporation - hydrochlorothiazide, lisinopril dihydrate - tabletti - 20 mg / 12.5 mg - lisinopriili ja diureetit
sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. kolmen lääkkeen yhdistelmähoito) lisänä ruokavalion ja liikunnan ohella potilaille riittävästi hallinnassa heidän maksimaalinen siedetty annos metformiinia ja sulfonyyliureaa. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
vildagliptin / metformin hydrochloride accord
accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 käytettävissä olevista tiedoista eri yhdistelmistä).